Liaoning Chengda Biotechnology Co.,Ltd. (SHA:688739)
China · Delayed Price · Currency is CNY 25.26
+0.34 (1.36%)
At close: Mar 6, 2026
SHA:688739 Revenue
In the year 2025, Liaoning Chengda Biotechnology had annual revenue of 1.39B CNY, down -17.06%. Liaoning Chengda Biotechnology had revenue of 294.40M in the quarter ending December 31, 2025, a decrease of -21.19%.
Revenue
1.39B
Revenue Growth
-17.06%
P/S Ratio
7.47
Revenue / Employee
769.39K
Employees
1,788
Market Cap
10.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.39B | -285.95M | -17.06% |
| Dec 31, 2024 | 1.68B | -73.86M | -4.22% |
| Dec 31, 2023 | 1.75B | -64.90M | -3.58% |
| Dec 31, 2022 | 1.81B | -273.04M | -13.08% |
| Dec 31, 2021 | 2.09B | 92.47M | 4.63% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.53B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.96B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 1.94B |
| Aurisco Pharmaceutical | 1.62B |
| Chengdu Easton Biopharmaceuticals | 1.33B |
| Hualan Biological Vaccine | 976.44M |
| HitGen | 525.57M |
| Beijing Hotgen Biotech | 407.69M |